Adalimumab (Humira®)

All Wales Medicines Strategy Group (AWMSG)

Record ID 32013000696

English

Authors' recommendations: Adalimumab (Humira®) is recommended as an option for use within NHS Wales, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis, in children aged 2 to 4 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 2 years.

Details

Project Status: Completed

Year Published: 2013

URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/1977

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

MeSH Terms

Antibodies, Monoclonal, Humanized
Anti-Inflammatory Agents

Contact

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.